Gamida Cell to Present NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline and Update on GDA-201 at Today's Virtual R&D Day - Form 6-K

Gamida Cell to Present NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline and Update on GDA-201 at Today's Virtual R&D Day




●

... | October 26, 2021

Related Keywords

Dana Farber Cancer Institute ,Massachusetts ,United States ,Boston ,American ,Courtney Turiano ,Rhiannon Jeselonis ,Julian Adams ,Ronit Simantov ,Stern Investor Relations Inc ,Twitter ,Drug Administration ,Nasdaq ,Exchange Commission ,American Society Of Hematology ,Gamida Cell Ltd ,Gamida Cell ,Genetically Modified ,Therapy Pipeline ,Clinical Hold ,New Drug ,Chief Executive Officer ,Therapy Programs ,Chief Medical Officer ,Annual Meeting ,Private Securities Litigation Reform Act ,Risk Factors ,Annual Report ,Investor Relations ,Gamida Cell Ltd Stock Exchange ,News ,Information ,Press Release ,Shamida ,Fell ,O ,Present ,Genetically ,Odified ,Uk ,Therapy ,Pipeline ,End ,Update ,N ,It ,Irtual Gmda Il0011552663 ,